Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.49 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 3/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17300184 | 0.84 | NPC1 (0.43) | SPHK1 | |
| SCHEMBL19375764 | 0.83 | SPHK1 (0.49) | SPHK1SLC1A3SLC1A2SLC1A1SPHK2 | |
| SCHEMBL2623846 | 0.82 | AAK1 (0.63) | SPHK1SPHK2AAK1 | |
| SCHEMBL2670047 | 0.78 | SPHK1 (0.45) | SPHK1SPHK2LTA4HAAK1S1PR1 | |
| SCHEMBL2670045 | 0.78 | SPHK1 (0.45) | SPHK1SPHK2LTA4HAAK1S1PR1 | |
| SCHEMBL17823130 | 0.78 | TAAR1 (0.60) | SPHK1SPHK2LTA4H | |
| SCHEMBL17823132 | 0.78 | TAAR1 (0.60) | SPHK1SPHK2LTA4H | |
| SCHEMBL17531810 | 0.78 | SLC1A3 (0.48) | SPHK1SLC1A3SLC1A2SLC1A1SPHK2 | |
| SCHEMBL22311657 | 0.78 | SLC1A3 (0.48) | SPHK1SLC1A3SLC1A2SLC1A1SPHK2 | |
| SCHEMBL26266218 | 0.77 | SPHK1 (0.68) | SPHK1SPHK2S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170232023-A1 | PEPTIDE-DRUG CONJUGATES | JIARAY PHARMACEUTICALS INC (KY) | 2017-08-17 | — | — | US | disclosed |
| US-9579317-B2 | Peptide-drug conjugates | JIARUI BIOPHARMACEUTICALS, LTD. (CN) | 2017-02-28 | — | — | US | disclosed |
| US-20150343083-A1 | PEPTIDE-DRUG CONJUGATES | JIARAY PHARMACEUTICALS, INC. (KY) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170232023-A1 | PEPTIDE-DRUG CONJUGATES | DNPEP, VIP, PEPD | SPHK1 4275/4885SLC1A3 301/4885SLC1A2 843/4885 |
| US-20150343083-A1 | PEPTIDE-DRUG CONJUGATES | DNPEP, VIP, PEPD | SPHK1 4275/4885SLC1A3 301/4885SLC1A2 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.